Kenvue stock price jumps 2% as KVUE takeover vote nears — what traders watch next

Kenvue Inc. shares rose about 2.2% to $17.77 on Thursday, recovering from a dip the previous day. By early afternoon, trading volume had already exceeded 43 million shares.

Kenvue Inc shares dropped roughly 1.7% to $17.29 Wednesday afternoon, despite a slight uptick in the broader market. Kimberly-Clark, the Kleenex maker set to acquire Kenvue, slipped around 1.8%. The consumer staples sector also remained under pressure.

Kenvue Inc shares edged down roughly 0.1% to $17.58 in early Wednesday trading, while Kimberly-Clark, the potential buyer, held steady at $101.44.

Kenvue shares ticked up 0.6% to $17.31 in late-morning trading Tuesday in New York, a modest gain as investors held back ahead of a late-January vote on the potential sale of the Tylenol and Band-Aid maker to Kimberly-Clark.

Kenvue shares slipped 0.35% to close at $17.20 on Friday, as investors digested a crucial nod for its planned sale to Kimberly-Clark. Proxy adviser Institutional Shareholder Services gave the green light, saying “on balance, support for the transaction is warranted.” Still, ISS flagged ongoing market jitters and legal risks as key concerns for shareholders. With proxy advisers often influencing big institutional votes, both companies’ investors are set to weigh in on Jan. 29.

Kenvue Inc shares ended slightly lower on Friday after proxy adviser ISS backed Kimberly-Clark’s takeover proposal, keeping attention on a shareholder vote later this month.

Kenvue Inc shares rose about 0.5% to $17.21 on Thursday, as Kimberly-Clark — the would-be buyer — gained roughly 0.7% to $99.81, lifting the implied value of the takeover offer. The broader market was firmer, with the S&P 500’s main ETF up about 0.6%, while the consumer staples ETF was little changed.

Kenvue Inc shares slipped on Friday, closing down about 1% at $16.83, as traders headed into the weekend still pricing in a gap to Kimberly-Clark’s takeover terms. Kimberly-Clark shares ended down about 1% at $97.92.

Kenvue Inc shares slipped 0.9% on Friday, ending at $16.83 after trading between $16.75 and $17.05, retracing some of Thursday’s gains. The Options Clearing Corporation highlighted a shareholder vote set for Jan. 29 on Kenvue’s proposed merger with Kimberly-Clark and detailed a planned adjustment to KVUE options once the deal closes. They warned terms might shift as new details emerge.

The Options Clearing Corporation on Friday announced a planned adjustment for Kenvue Inc. options before the Jan. 29 shareholder vote on the company’s proposed merger with Kimberly-Clark. Kenvue shares last changed hands at $16.83, slipping roughly 1% after U.S. markets closed.

Kenvue Inc shares rose 0.8% to $16.87 in mid-morning trade on Thursday after shareholder law firm Kahn Swick & Foti said it was investigating the consumer health group’s pending sale to Kimberly-Clark. The firm said it is reviewing whether Kenvue’s board ran a fair process and secured the best price for shareholders. PR Newswire

Kenvue Inc.—the consumer health company behind brands such as Tylenol, Band-Aid, Listerine, Neutrogena, and Aveeno—is trading in a market that feels less like “buy-and-hold fundamentals” and more like “event-driven probability.” The reason: Kimberly-Clark’s planned acquisition of Kenvue, a deal that has put a very visible “price anchor” on KVUE… while lawsuits, regulatory steps, and the calendar to closing keep the stock from simply snapping to the offer value. investors.kenvue.com+2Reuters+2